GILD Q2 2026: A Big IPR&D Drag Dampens EPS as Revenue Keeps Growing

Gilead Sciences Inc., ticker GILD, reported its second-quarter 2026 results with a clear bifurcation: total revenue rose 10% year over year to about $7.8 billion, driven by a robust product lineup excluding Veklury. But per-share metrics took a brutal haircut from acquired in-process research & development charges, producing an EPS of $(8.45) and a Non-GAAP EPS of $(6.75). If you’re chasing an earnings surprise or EPS consensus story for the quarter, the headline numbers look like a miss born from a heavy one-time drag rather than a signal about the core business. Still, management frames the underlying base business as resilient, even as it pivots toward an M&A-driven growth path and a leaner balance sheet.

Financial highlights at a glance

Total second-quarter 2026 revenues: $7.8 billion, up 10% from the prior year. Product sales excluding Veklury rose 10% to $7.6 billion, highlighting strength in the HIV portfolio and other franchises.

Biktarvy sales increased 7% year over year to $3.8 billion, underscoring continued demand in HIV therapies. HIV sales overall grew about 12%, contributing to the top-line momentum even as other segments faced mixed conditions.

Diluted loss per share: $(8.45). Non-GAAP diluted loss per share: $(6.75). The negative EPS was largely driven by a $9.08 per-share impact from acquired IPR&D and related taxes tied to recent acquisitions (Arcellx, Tubulis, Ouro Medicines, and related collaborations). Higher non-GAAP SG&A and non-GAAP tax expense also weighed on the headline figures.

What the executives said

Foster City, CA, remains the backdrop for the drumbeat of capital allocation. In the release, Daniel O’Day, Gilead’s Chairman and CEO, pointed to “three FDA approvals and three positive Phase 3 updates,” while signaling a continued push into oncology and HIV with potential launches in the second half of the year. The message: the company is betting on clinical progress and a more selective, capital-efficient growth trajectory.

Operating cash flow and cash position: the cash tug-of-war

Operating cash flow for the quarter stood at $3.6 billion. For the six months ended June 30, 2026, cash flow dynamics were dominated by acquisitions: year-to-date cash outflows related to acquisitions totaled about $11.3 billion, with $2.8 billion in debt repayments, $2.1 billion in dividend payments, and $774 million in common stock repurchases.

Net cash flows were further shaped by financing and operating activities: management highlighted $4.1 billion of net proceeds from debt financing and $6.1 billion of operating cash flow, offsetting the drag from acquisitions. As of June 30, 2026, the company reported $3.2 billion in cash, cash equivalents and marketable debt securities, down from $10.6 billion at year-end 2025—an intentional reminder that the pipeline chase comes with a short-run balance-sheet cost.

Outlook and the revenue forecast tilt

The press release notes management’s expectation to raise the base business revenue outlook for 2026, signaling containment of the near-term drag and a belief that core franchises can support higher medium-term revenue in the full-year context. The narrative hinges on continued HIV portfolio strength and the maturation of late-stage programs, even as M&A-driven IPR&D charges stay in focus for earnings reporting.

In practical terms, investors will be watching whether the EPS headwind from IPR&D and taxes is a one-off that fades as new products and existing franchises scale, or a longer-lasting hurdle. If you’re scanning for a revenue forecast that aligns with the company’s strategic shifts, the Q2 call and subsequent updates will be the place to look for a clearer signal about 2026 and beyond.

What this could portend for peers and the sector

Gilead’s quarterly story is a familiar one in large-cap biopharma: strong top-line momentum masked by large, non-cash or one-time charges tied to acquisitions and IPR&D. The takeaway for sector peers is a reminder that earnings optics can be heavily skewed by deal-driven charges even when core drugs demonstrate ongoing performance. For investors, the question becomes whether the pipeline, pipeline-related costs, and the balance-sheet discipline can translate into durable earnings power as new products mature.

For peers with similar M&A activity, the emphasis will likely shift toward the quality of acquired assets, the timing of IPR&D amortization, and the trajectory of free cash flow after deal-related outlays. If GILD’s debt financing and operating cash flow narrative holds, the sector could see a modest pressure on near-term EPS prints but a more stable revenue growth story as the pipeline and HIV portfolio continue to contribute.

Bottom line

Gilead’s Q2 2026 results illustrate a company juggling acute short-term EPS gravity from IPR&D with a longer-term revenue growth aspiration anchored in HIV products and a revitalized pipeline. Investors get a two-track picture: top-line resilience (+10% revenue) and a bottom-line hit dominated by one-time charges rather than a structural erosion of the business. The real test will be whether the improved revenue outlook sticks and if the base business can deliver meaningful margin expansion as acquisitions begin to bear fruit, or at least as the dust settles from the IPR&D charge book.